- Home
- SACH vs SKYE Comparison
SACH vs SKYE Comparison
Compare SACH & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- SKYE
- Stock Information
- Founded
- SACH 2010
- SKYE 2012
- Country
- SACH United States
- SKYE United States
- Employees
- SACH N/A
- SKYE N/A
- Industry
- SACH Real Estate Investment Trusts
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- SKYE Health Care
- Exchange
- SACH Nasdaq
- SKYE Nasdaq
- Market Cap
- SACH 50.6M
- SKYE 46.5M
- IPO Year
- SACH 2017
- SKYE N/A
- Fundamental
- Price
- SACH $1.06
- SKYE $1.55
- Analyst Decision
- SACH Hold
- SKYE Strong Buy
- Analyst Count
- SACH 4
- SKYE 5
- Target Price
- SACH $2.00
- SKYE $14.75
- AVG Volume (30 Days)
- SACH 138.0K
- SKYE 568.6K
- Earning Date
- SACH 11-05-2025
- SKYE 11-10-2025
- Dividend Yield
- SACH 18.87%
- SKYE N/A
- EPS Growth
- SACH N/A
- SKYE N/A
- EPS
- SACH N/A
- SKYE N/A
- Revenue
- SACH $4,046,000.00
- SKYE N/A
- Revenue This Year
- SACH N/A
- SKYE N/A
- Revenue Next Year
- SACH $6.63
- SKYE N/A
- P/E Ratio
- SACH N/A
- SKYE N/A
- Revenue Growth
- SACH N/A
- SKYE N/A
- 52 Week Low
- SACH $0.80
- SKYE $1.14
- 52 Week High
- SACH $2.24
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- SACH 40.74
- SKYE 38.64
- Support Level
- SACH $1.04
- SKYE $1.42
- Resistance Level
- SACH $1.10
- SKYE $1.60
- Average True Range (ATR)
- SACH 0.03
- SKYE 0.10
- MACD
- SACH 0.00
- SKYE 0.08
- Stochastic Oscillator
- SACH 14.50
- SKYE 74.31
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.